|
86 Companies |
|
134 Products |
|
134 Products |
|
85 Mechanisms of Action |
|
5 Trials |
|
1881 News |
|
| «12...7891011121314151617...3738» |
- Enrollment closed: Pregnenolone for Cognitive and Negative Symptoms in Schizophrenia (clinicaltrials.gov) - Apr 28, 2015
P2, N=88, Active, not recruiting, Sponsor: Department of Veterans Affairs
Recruiting --> Active, not recruiting
- |||| risperidone / Generic mfg.
Trial completion: Study Of Talnetant Versus Placebo And Risperidone In Schizophrenia (clinicaltrials.gov) - Apr 27, 2015
P2, N=282, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Recruiting --> Completed
- Enrollment closed: AHCM: Addiction Housing Case Management for Homeless Veterans (clinicaltrials.gov) - Apr 22, 2015
P=N/A, N=400, Active, not recruiting, Sponsor: Department of Veterans Affairs
Recruiting --> Completed Recruiting --> Active, not recruiting
- Adcetris (brentuximab vedotin) / Takeda, Pfizer
Trial primary completion date: Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma (clinicaltrials.gov) - Apr 22, 2015
P2, N=57, Recruiting, Sponsor: City of Hope Medical Center
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2015 --> Sep 2016
- risperidone / Generic mfg., desipramine / Generic mfg.
Trial completion, Enrollment change: RADIAUS: Risperidone and Desipramine in Alcohol Use and Schizophrenia (clinicaltrials.gov) - Apr 20, 2015
P2, N=12, Completed, Sponsor: Dartmouth-Hitchcock Medical Center
Trial primary completion date: Dec 2015 --> Sep 2016 Active, not recruiting --> Completed | N=40 --> 12
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial primary completion date: Linagliptin in Schizophrenia Patients (clinicaltrials.gov) - Apr 20, 2015
P1, N=5, Recruiting, Sponsor: Monash University
Active, not recruiting --> Completed | N=40 --> 12 Trial primary completion date: Oct 2014 --> Oct 2016
- Kuvan (sapropterin) / Merck (MSD), BioMarin, Daiichi Sankyo
Trial primary completion date: Kuvan in People With Schizophrenia and Schizoaffective Disorder (clinicaltrials.gov) - Apr 19, 2015
P1/2, N=60, Suspended, Sponsor: New York State Psychiatric Institute
Trial primary completion date: Oct 2014 --> Oct 2016 Trial primary completion date: Jun 2014 --> Sep 2015
- Clinical data, Trial primary completion date: Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis (clinicaltrials.gov) - Apr 19, 2015
P=N/A, N=264, Recruiting, Sponsor: North Shore Long Island Jewish Health System
Trial primary completion date: Jun 2014 --> Sep 2015 Trial primary completion date: Mar 2015 --> Mar 2019
- | quetiapine / Generic mfg.
Trial completion, Trial primary completion date: High Dose of Quetiapine in Treating Subjects With Treatment Refractory Schizophrenia or Schizoaffective Disorder (clinicaltrials.gov) - Apr 17, 2015
P2/3, N=60, Completed, Sponsor: Manhattan Psychiatric Center
Trial primary completion date: Mar 2015 --> Mar 2019 Active, not recruiting --> Completed | Trial primary completion date: Oct 2009 --> Oct 2014
- Enrollment open, Trial initiation date, Trial primary completion date: A Trial of Folate With B12 in Patients With Schizophrenia With Residual Symptoms in Ethiopia (clinicaltrials.gov) - Apr 16, 2015
P4, N=240, Recruiting, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed | Trial primary completion date: Oct 2009 --> Oct 2014 Not yet recruiting --> Recruiting | Initiation date: Jun 2014 --> Nov 2014 | Trial primary completion date: Jun 2015 --> Jun 2016
- ||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Trial completion, Head-to-Head: Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia (clinicaltrials.gov) - Apr 16, 2015
P3, N=1430, Completed, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting | Initiation date: Jun 2014 --> Nov 2014 | Trial primary completion date: Jun 2015 --> Jun 2016 Active, not recruiting --> Completed
- | Rexulti (brexpiprazole) / Lundbeck, Otsuka
Trial completion: PET Trial to Assess the Receptor Occupancy of Brexpiprazole in Adult Subjects With Schizophrenia (clinicaltrials.gov) - Apr 16, 2015
P1, N=12, Completed, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Active, not recruiting --> Completed Recruiting --> Completed
- | clozapine orally disintegrating tablets / Generic mfg.
Trial completion, Enrollment change: Equivalence of Generic Clozapine to Orally Dissolving Clozapine in Schizophrenia or Schizoaffective Disorder (clinicaltrials.gov) - Apr 15, 2015
P4, N=20, Completed, Sponsor: Manhattan Psychiatric Center
Recruiting --> Completed Active, not recruiting --> Completed | N=30 --> 20
- Trial initiation date, Trial primary completion date: RISE (Rehabilitation Intervention for People With Schizophrenia in Ethiopia) (clinicaltrials.gov) - Apr 15, 2015
P=N/A, N=180, Not yet recruiting, Sponsor: London School of Hygiene and Tropical Medicine
Active, not recruiting --> Completed | N=30 --> 20 Initiation date: Mar 2015 --> Jun 2015 | Trial primary completion date: Dec 2015 --> Mar 2016
- ||||||| Trial completion: NEUROCOM: Neurocognitive Training Integrated in OPUS Treatment Versus OPUS Treatment-as-usual (clinicaltrials.gov) - Apr 15, 2015
P3, N=117, Completed, Sponsor: Neurocom
Initiation date: Mar 2015 --> Jun 2015 | Trial primary completion date: Dec 2015 --> Mar 2016 Active, not recruiting --> Completed
- aripiprazole / Generic mfg., olanzapine / Generic mfg.
Trial completion, Trial primary completion date, Adherence: Adherence in Patients Admitted to a Psychiatric Unit for Acute Psychosis: an Analysis of Serum Levels of Antipsychotics. (clinicaltrials.gov) - Apr 14, 2015
P=N/A, N=106, Completed, Sponsor: North Shore Long Island Jewish Health System
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Dec 2014 --> Apr 2015
- |||| Rexulti (brexpiprazole) / Lundbeck, Otsuka
Trial primary completion date: A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial (clinicaltrials.gov) - Apr 14, 2015
P3, N=2363, Recruiting, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting --> Completed | Trial primary completion date: Dec 2014 --> Apr 2015 Trial primary completion date: May 2016 --> Sep 2016
- |||| Rexulti (brexpiprazole) / Lundbeck, Otsuka
Trial primary completion date: Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial) (clinicaltrials.gov) - Apr 14, 2015
P3, N=3000, Active, not recruiting, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Trial primary completion date: May 2016 --> Sep 2016 Trial primary completion date: Nov 2016 --> Feb 2017
- eltoprazine (DU 28853) / Amarantus BioSci, PsychoGenics, ReqMed
Trial completion, Enrollment change: Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults (clinicaltrials.gov) - Apr 14, 2015
P2, N=31, Completed, Sponsor: Amarantus BioScience Holdings, Inc.
Trial primary completion date: Nov 2016 --> Feb 2017 Recruiting --> Completed | N=50 --> 31
- Enrollment change: Mindfulness Meditation as a Rehabilitation Strategy for Persons With Schizophrenia (clinicaltrials.gov) - Apr 13, 2015
P=N/A, N=34, Completed, Sponsor: Department of Veterans Affairs
Recruiting --> Completed | N=50 --> 31 N=52 --> 34
- methylphenidate prolonged release tablet - 12 hrs acting / Generic mfg.
Trial completion, Combination therapy: A Study of Combination Therapy in Children With ADHD (clinicaltrials.gov) - Apr 10, 2015
P4, N=99, Completed, Sponsor: Douglas Sears
N=52 --> 34 Active, not recruiting --> Completed
- Enrollment open: Emotional Intelligence in Schizophrenia and Bipolar-I- Disorder (clinicaltrials.gov) - Apr 9, 2015
P=N/A, N=300, Recruiting, Sponsor: Medical University Innsbruck
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- pimozide / Generic mfg., clozapine / Generic mfg.
Trial completion: Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia (clinicaltrials.gov) - Apr 9, 2015
P4, N=76, Completed, Sponsor: Mount Sinai School of Medicine
Not yet recruiting --> Recruiting Recruiting --> Completed
- Trial completion: Life Goals Behavioral Change to Improve Outcomes for Veterans With Serious Mental Illness (clinicaltrials.gov) - Apr 7, 2015
P=N/A, N=55, Completed, Sponsor: Department of Veterans Affairs
Recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Evaluating a Collaborative Care Model for the Treatment of Schizophrenia (EQUIP) (clinicaltrials.gov) - Apr 5, 2015
P=N/A, N=443, Completed, Sponsor: Department of Veterans Affairs
Active, not recruiting --> Completed No longer recruiting --> Completed
- | Trial completion: Psychiatric Advance Directives for Improved Mental Health Care (clinicaltrials.gov) - Apr 5, 2015
P=N/A, N=360, Completed, Sponsor: Department of Veterans Affairs
No longer recruiting --> Completed No longer recruiting --> Completed
- | Trial completion, Adherence: Improving Antipsychotic Adherence Among Patients With Serious Mental Illness (clinicaltrials.gov) - Apr 5, 2015
P=N/A, N=150, Completed, Sponsor: Department of Veterans Affairs
No longer recruiting --> Completed No longer recruiting --> Completed
- Trial completion, HEOR, Cost effectiveness: MANAS: Evaluating the Benefits and Affordability of a Program to Improve the Care of Common Mental Disorders in Primary Care (clinicaltrials.gov) - Apr 1, 2015
P=N/A, N=2796, Completed, Sponsor: London School of Hygiene and Tropical Medicine
No longer recruiting --> Completed Active, not recruiting --> Completed
- |||| amisulpride / Generic mfg., clozapine / Generic mfg.
Trial completion, Enrollment change: AMICUS: Amisulpride Augmentation in Clozapine-unresponsive Schizophrenia (clinicaltrials.gov) - Apr 1, 2015
P4, N=69, Completed, Sponsor: Imperial College London
Active, not recruiting --> Completed Recruiting --> Completed | N=230 --> 69
- Trial completion: A Definitive Estrogen Patch Study (ADEPT) (clinicaltrials.gov) - Apr 1, 2015
P2, N=180, Completed, Sponsor: The Alfred
Recruiting --> Completed | N=230 --> 69 Active, not recruiting --> Completed
- |||| citalopram / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date, HEOR, Cost effectiveness: ACTIONS: Antidepressant Controlled Trial for Negative Symptoms in Schizophrenia (clinicaltrials.gov) - Mar 26, 2015
P4, N=62, Completed, Sponsor: Imperial College London
Active, not recruiting --> Completed Recruiting --> Completed | N=358 --> 62 | Trial primary completion date: Jan 2014 --> Dec 2014
- Enrollment closed: Cognitive Behavior Therapy and Work Outcome (clinicaltrials.gov) - Mar 25, 2015
P=N/A, N=120, Active, not recruiting, Sponsor: Department of Veterans Affairs
Recruiting --> Completed | N=358 --> 62 | Trial primary completion date: Jan 2014 --> Dec 2014 Recruiting --> Active, not recruiting
- Trial completion: Feedback and Psychotherapeutic Competencies (clinicaltrials.gov) - Mar 20, 2015
P=N/A, N=20, Completed, Sponsor: Goethe University
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Trial completion: Smoking Cessation for Veterans With Severe and Persistent Mental Illness (clinicaltrials.gov) - Mar 20, 2015
P2/3, N=179, Completed, Sponsor: Department of Veterans Affairs
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Phase classification: Fingolimod in Schizophrenia Patients (clinicaltrials.gov) - Mar 17, 2015
P2, N=40, Recruiting, Sponsor: Indiana University
Active, not recruiting --> Completed Phase classification: P1 --> P2
- ||| olanzapine / Generic mfg.
Trial completion: eVAluatIon of OLanzapine TreatmEnT (clinicaltrials.gov) - Mar 17, 2015
P=N/A, N=468, Completed, Sponsor: Elpen Pharmaceutical Co. Inc.
Phase classification: P1 --> P2 Recruiting --> Completed
- Trial completion, Enrollment change: Reducing Weight and Diabetes Risk in an Underserved Population (STRIDE) (clinicaltrials.gov) - Mar 17, 2015
P2, N=200, Completed, Sponsor: Kaiser Permanente
Recruiting --> Completed Active, not recruiting --> Completed | N=280 --> 200
- Enrollment open: REACH: Researching the Effectiveness of Acceptance-Based Coping During Hospitalization (clinicaltrials.gov) - Mar 12, 2015
P=N/A, N=60, Recruiting, Sponsor: Butler Hospital
Active, not recruiting --> Completed | N=280 --> 200 Not yet recruiting --> Recruiting
- Aristada once-monthly (aripiprazole lauroxil once-monthly formulation) / Alkermes, Aristada two-month (aripiprazole lauroxil XR) / Alkermes
Enrollment open: An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia (clinicaltrials.gov) - Mar 11, 2015
P1, N=140, Recruiting, Sponsor: Alkermes, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Trial completion: Auditory Verbal Hallucinations in Schizophrenia (clinicaltrials.gov) - Mar 10, 2015
P=N/A, N=40, Completed, Sponsor: University Hospital, Grenoble
Not yet recruiting --> Recruiting Recruiting --> Completed
- Enrollment closed, Trial primary completion date: Treatment Development Targeting Severe and Persistent Negative Symptoms (clinicaltrials.gov) - Mar 7, 2015
P=N/A, N=50, Active, not recruiting, Sponsor: The University of Texas Health Science Center at San Antonio
Recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2014 --> Aug 2014
- Trial completion, Adherence: Improving Adherence to Oral Antipsychotic Medications in People With Schizophrenia (clinicaltrials.gov) - Mar 7, 2015
P=N/A, N=150, Completed, Sponsor: The University of Texas Health Science Center at San Antonio
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2014 --> Aug 2014 Active, not recruiting --> Completed
- | Lu AF11167 / Lundbeck
Trial completion: Pharmacokinetic Properties of Various Modified Release Tablet Formulations of Lu AF11167 (clinicaltrials.gov) - Mar 7, 2015
P1, N=28, Completed, Sponsor: H. Lundbeck A/S
Active, not recruiting --> Completed Recruiting --> Completed
- ||| Lu AF35700 / Lundbeck, Jiangsu NHWA Pharma
Trial completion: Safety and Tolerability Study of Lu AF35700 After Repeated Dosing in Patients With Schizophrenia (clinicaltrials.gov) - Mar 7, 2015
P1, N=96, Completed, Sponsor: H. Lundbeck A/S
Recruiting --> Completed Recruiting --> Completed
- | Enrollment closed, Trial primary completion date: CHANGE -it is About Life (clinicaltrials.gov) - Mar 5, 2015
P3, N=430, Active, not recruiting, Sponsor: Mental Health Services in the Capital Region, Denmark
Recruiting --> Completed Not yet recruiting --> Active, not recruiting | Trial primary completion date: Aug 2016 --> May 2016
- Rykindo (risperidone extended release microspheres) / Luye Group
Trial primary completion date: An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder (clinicaltrials.gov) - Mar 5, 2015
P1, N=16, Enrolling by invitation, Sponsor: Luye Pharma Group Ltd.
Not yet recruiting --> Active, not recruiting | Trial primary completion date: Aug 2016 --> May 2016 Trial primary completion date: Nov 2014 --> May 2015
- ||| Rykindo (risperidone extended release microspheres) / Luye Group
Trial completion, Phase classification: Bioavailability of LY03004 and Risperdal® Consta® (clinicaltrials.gov) - Mar 5, 2015
P1, N=108, Completed, Sponsor: Luye Pharma Group Ltd.
Trial primary completion date: Nov 2014 --> May 2015 Recruiting --> Completed | Phase classification: P1/2 --> P1
- Trial completion: Pharmacologic and Clinical Testing of a D1 Agonist for Cognitive Enhancement in Neuropsychiatric Disorders (clinicaltrials.gov) - Mar 5, 2015
P0, N=68, Completed, Sponsor: New York State Psychiatric Institute
Recruiting --> Completed | Phase classification: P1/2 --> P1 Active, not recruiting --> Completed
- Trial completion, Trial primary completion date: MCT: Metacognitive Training in Schizophrenia (clinicaltrials.gov) - Mar 3, 2015
P=N/A, N=60, Completed, Sponsor: Universitätsklinikum Hamburg-Eppendorf
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: May 2012 --> Dec 2013
- || pregabalin / Generic mfg.
Trial primary completion date: PACS: Pregablin for Anxiety-comorbidity in Patients With Schizophrenia (clinicaltrials.gov) - Feb 27, 2015
P4, N=70, Recruiting, Sponsor: University of Aarhus
Active, not recruiting --> Completed | Trial primary completion date: May 2012 --> Dec 2013 Trial primary completion date: Dec 2014 --> Feb 2016